- In early August 2026, CVS Health reported second-quarter sales of US$35,117 million and net income of US$2,979 million, while raising full-year GAAP diluted EPS guidance to US$6.84–US$7.04 and projecting at least US$414.00 billion in revenue and up to US$9.07 billion in net income attributable to CVS Health.
- At the same time, CVS Health overhauled its weight management offering around GLP-1 therapies, cutting MinuteClinic digital visit prices to US$29 and partnering with Eli Lilly to integrate transparent GLP-1 pricing and access through the CVS Health app across roughly 9,000 pharmacies.
- We’ll now examine how this combination of stronger earnings guidance and an expanded GLP-1 weight management platform affects CVS Health’s investment narrative.
Uncover the next big thing with 18 elite penny stocks that balance risk and reward
Advertisement
CVS Health Investment Narrative Recap
To own CVS Health, you need to believe its integrated model of insurance, pharmacy and care delivery can turn scale into consistent, profitable growth despite reimbursement and medical cost pressures. The raised 2026 earnings guidance reinforces near term confidence in execution, while the biggest current risk remains margin and medical cost pressure in Health Care Delivery and Medicare Advantage. The latest results and outlook do not remove that risk, but they do suggest it is not worsening right now.
The revamped GLP 1 weight management program and Eli Lilly collaboration matter because they sit at the intersection of CVS’s digital investments and its pharmacy and care delivery footprint. If GLP 1 therapies remain a meaningful category, CVS’s 9,000 pharmacies, $29 MinuteClinic visits and app based pricing tools could support one of the key long term catalysts around deeper engagement and cross sell across its ecosystem
But investors should also weigh how continuing reimbursement pressure at retail and in the PBM business could
Read the full narrative on CVS Health (it’s free!)
CVS Health’s narrative projects $453.4 billion revenue and $10.7 billion earnings by 2029. This requires 3.8% yearly revenue growth and a $7.8 billion earnings increase from $2.9 billion today
Uncover how CVS Health’s forecasts yield a $114.88 fair value, a 18% upside to its current price
Exploring Other Perspectives
Four members of the Simply Wall St Community currently see CVS Health’s fair value between US$104 and US$281 per share, reflecting very different expectations. When you set those views against the recent earnings guidance increase and GLP 1 expansion, it underlines how differently investors can weigh upside potential against reimbursement and medical cost risks, so it is worth comparing several viewpoints before forming your own
Explore 4 other fair value estimates on CVS Health – why the stock might be worth just $104.01!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts
- A great starting point for your CVS Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free CVS Health research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate CVS Health’s overall financial health at a glance.
Searching For A Fresh Perspective?
Markets shift fast. These stocks won’t stay hidden for long. Get the list while it matters:
- The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.
- The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- We’ve uncovered the 10 dividend fortresses yielding 5%+ that don’t just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities
• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics
Explore Now for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
mitchell_lawler
The Foxhole
Micron (MU) is booming, and it still doesn’t look ‘expensive’ based on next year’s earnings. So why does our own valuation say it could be worth 40% less?
1610
zoe_vi5fn24h
A low price to earnings ratio at the top of the cycle is a warning rather than a bargain, and a terrifyingly high one at the bottom is often the entry point
darius_xnnrd24h
Memory used to have a dozen participants racing each other into oversupply, and now it has three. High bandwidth memory is qualified into customer designs years ahead, sold under long-term agreements, and is far harder to switch away from than commodity DRAM
About NYSE:CVS
CVS Health
Provides health solutions in the United States
See The Free Research Report
Established dividend payer and fair value
See The Free Research Report
Similar Companies
Cigna Group
NasdaqGS:PRVA
Privia Health Group
Market Insights
Picking portfolio winners takes more than hot airAndrew Legget
What Korea’s market says about your index fundMitchell Lawler
What does frontier-beating open source mean for AI investors?Andrew Legget
Advertisement
Weekly Picks
RI
Rick_Orfordon Starfighters Space·8 days ago
The 1960s Fighter Jet That Could Crack Open a $20 Billion Satellite Market
Fair Value:US$515.2% undervalued
28followersusers have followed this narrative
·1commentusers have commented on this narrative
·5likesusers have liked this narrative
FU
FundamentalFlowon Vertiv Holdings Co·12 days ago
The Short and Long Term Compounder of Liquid Cooling industry
Fair Value:US$45034.7% undervalued
57followersusers have followed this narrative
·0commentsusers have commented on this narrative
·13likesusers have liked this narrative
JO
John_Ericon SPX Technologies·7 days ago
I Fell in Love With a Data-Center Cooling Stock. Then I Opened the Filings
Fair Value:US$2037.1% overvalued
22followersusers have followed this narrative
·2commentsusers have commented on this narrative
·6likesusers have liked this narrative
TR
tripledubon GQG Partners·2 days ago
The Cheap Genius Problem
Fair Value:AU$3.2155.0% undervalued
34followersusers have followed this narrative
·0commentsusers have commented on this narrative
·22likesusers have liked this narrative
RecentlyUpdated Narratives
RO
RockeTelleron Vault Minerals·about 3 hours ago
Vault Minerals: Debt-Free Gold Producer with 700Koz+ Potential
Fair Value:AU$8.6731.8% undervalued
17followersusers have followed this narrative
·1commentusers have commented on this narrative
·1likeusers have liked this narrative
CO
Conrad_Egusaon Grupo Cibest·about 9 hours ago
Why Bancolombia’s undervaluation offers investment upside
Fair Value:Col$91.69k3.7% undervalued
2followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
GE
GeraldBuffeton Logindo Samudramakmur·about 15 hours ago
LEAD: The Offshore Recovery Opportunity
Fair Value:Rp95588.8% undervalued
2followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
OS
oscargarciaon NVIDIA·2 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century
Fair Value:US$28019.6% undervalued
310followersusers have followed this narrative
·9commentsusers have commented on this narrative
·16likesusers have liked this narrative
CU
CubanEroson Microsoft·about 1 month ago
A wonderful business at reasonable price
Fair Value:US$419.9118.0% overvalued
168followersusers have followed this narrative
·0commentsusers have commented on this narrative
·8likesusers have liked this narrative
KI
KiwiInveston Amazon.com·3 months ago
Amazon’s high growth, high tech segments propel its profits, while traditional segments plod along
Fair Value:US$475.0944.7% undervalued
189followersusers have followed this narrative
·1commentusers have commented on this narrative
·8likesusers have liked this narrative
